Elite Pharmaceuticals (ELTP) Q4 2024 earnings summary

Executive summary

• Fiscal year ending March 31, 2024, delivered record revenues of $56.6 million, up 65% year-over-year, driven by the commercial launch of the Elite label product line.

• Operating income rose to $10.8 million, a 192% increase from the prior year.

• Net income attributable to common shareholders was $20.1 million, boosted by a one-time, non-cash income tax benefit.

• Transitioned from a CMO/private label model to direct sales under the Elite label, driving significant revenue and profit growth.

• CEO projects a minimum of $70 million in revenue for fiscal year ending March 2025, reflecting strong confidence in the current run rate and pipeline.

Financial highlights

• Revenue increased to $56.6 million from $34.2 million year-over-year, a $22.4 million or 65% rise.

• Operating profit grew by $7.1 million year-over-year, reaching $10.8 million.

• Net income reached $20 million, supported by a $19.6 million deferred tax asset benefit.

• Operating cash flow was negative $3.3 million, compared to positive $3.3 million the prior year, due to increased working capital needs from rapid growth.

• Working capital doubled to $28 million, and net equity doubled to $58 million.

Outlook and guidance

• Management forecasts at least $70 million in revenue for fiscal year ending March 2025.

• Four newly approved or acquired ANDAs expected to contribute to future revenue.

• R&D pipeline includes three ANDAs under FDA review, with at least two considered potential major revenue drivers.